Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10962885 | 0.79 | CA1 (0.32) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10039231 | 0.78 | CA1 (0.48) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL8666163 | 0.77 | — | — | |
| SCHEMBL10629834 | 0.74 | — | — | |
| SCHEMBL2734239 | 0.74 | — | — | |
| SCHEMBL28992477 | 0.72 | CA1 (0.32) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14225540 | 0.70 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL11596567 | 0.70 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL7920518 | 0.68 | CA1 (0.40) | CA1CA2 | |
| Dimethylamine SCHEMBL5971936 | 0.68 | USP2 (0.52) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180123123-A1 | LITHIUM ION SECONDARY BATTERY | NEC CORP (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180090792-A1 | LITHIUM ION SECONDARY BATTERY AND METHOD FOR MANUFACTURING SAME | NEC CORPORATION (JP) | 2018-03-29 | — | — | US | disclosed |
| US-20180076479-A1 | LITHIUM-ION SECONDARY CELL AND METHOD FOR MANUFACTURING SAME | NEC CORPORATION (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180076449-A1 | NEGATIVE ELECTRODE FOR LITHIUM ION SECONDARY BATTERY AND SECONDARY BATTERY | NEC CORPORATION (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180053935-A1 | LITHIUM ION SECONDARY BATTERY | NEC CORPORATION (JP) | 2018-02-22 | — | — | US | disclosed |
| US-9847180-B2 | Nonaqueous electrolyte solution, and lithium ion secondary battery having the same | NEC ENERGY DEVICES, LTD. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-9847180-B2 | Nonaqueous electrolyte solution, and lithium ion secondary battery having the same | NEC ENERGY DEVICES, LTD. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-9620812-B2 | Lithium ion battery | NEC ENERGY DEVICES, LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-9620812-B2 | Lithium ion battery | NEC ENERGY DEVICES, LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-9343740-B2 | Lithium ion battery | NEC ENERGY DEVICES, LTD. (JP) | 2016-05-17 | — | — | US | disclosed |
| US-20110274982-A1 | LITHIUM ION BATTERY | NEC ENERGY DEVICES, LTD. | 2011-11-10 | — | — | US | disclosed |
| US-20100092869-A1 | LITHIUM ION BATTERY | NEC TOKIN CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100092869-A1 | LITHIUM ION BATTERY | NEC TOKIN CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100062332-A1 | LITHIUM ION SECONDARY BATTERY | NEC TOKIN CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070154815-A1 | Secondary battery | NEC CORPORATION (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070154815-A1 | Secondary battery | NEC CORPORATION (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | KDM4E 543/4885USP2 677/4885ALDH1A1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.